The invention relates to an anhydrous crystalline form of (1,1-dioxo-hexahydro-1lambda*6*- thiopyran-4-yl)-{(S)-3-[1-(6-methoxy-5-methyl-pyridin-3-yl)-2,3-dihydro-1H-pyrido[3,4-b][1,4]oxazin-7-yloxy]-pyrrolidin-1-yl}-methanone pharmaceutical compositions and combinations including these forms as well as to methods of using these forms, including their pharmaceutical compositions and combinations for the treatment of diseases.本發明係關於(1,1-二側氧基-六氫-1λ*6*-硫代哌喃-4-基)-{(S)-3-[1-(6-甲氧基-5-甲基-吡啶-3-基)-2,3-二氫-1H-吡啶并[3,4-b][1,4]-7-基氧基]-吡咯啶-1-基}-甲酮之無水結晶形式;包括此等形式之醫藥組合物及組合;以及使用此等形式(包括其醫藥組合物及組合)治療疾病之方法。
